ReviewFrontiers in artificial intelligence2026
Deep learning for cardiovascular disease: a comprehensive review of detection and risk forecasting.
Review in Frontiers in artificial intelligence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The biggest health threat to the global population is cardiovascular disease (CVD), which afflicts almost one-third of the global population and causes considerable monetary and social losses. Risk analysis should be performed in a timely and appropriate manner to enhance clinical practice and preventive interventions. The emergence of advanced data modalities, such as wearable sensors, medical imaging, electronic health records (EHRs), and genomic platforms, has led to a paradigm shift in the holistic assessment of CVD risk through multimodal data integration. This systematic review is a methodological analysis of recent multimodal input deep-learning algorithms that enhance the early detection of CVD and risk-specific evaluation, following PRISMA 2020 guidelines across 69 studies published 20,122,025 based on 2,847 initial database records. We characterized the wide range of available data streams: longitudinal physiological measurements (ECG, HRV, and BP), echocardiogram data, cardiac MRI and CT, lab/demographic data, behavioral/environmental data, and genomic/proteomic data. Mid-level, early, late, and attention-based fusion methods are described in the context of deep neural networks, such as CNNs, RNNs, BiGRU with attention, and hybrid CNN-LSTM networks. Comparative studies showed dramatic improvements in predictive accuracy (often over 98%), strength to missing or noisy modalities, and access to real-time, individualized recommendations. The best-performing DEEP-CARDIO BiGRU-Attention model had 99.9 percent accuracy on Framingham and Statlog benchmarks. A systematic review of 28 studies by Grad-CAM and SHAP confirmed the dominance of each in imaging and structured-data tasks, respectively (Rahman et al., 2024). The federated explainable FL-LSTM model achieved 99% AUC across three ECG databanks with complete privacy protection. We end with a systematic reproducibility, federated learning, equitable AI, and regulatory translation roadmap.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.